Findings

What do systematic reviews say?

Ignored "PE": search terms need at least 3 characters.

465 questions · 491 findings · 45 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 117 · 23.8%GRADE not reported 35 · 7.1%Very low 131 · 26.7%Low 133 · 27.1%Moderate 61 · 12.4%High 14 · 2.9%

Dalteparin vs placebo

Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Pain durationScale from: 1 to 7. · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Tinzaparin vs placebo

The requirement for opiate treatment · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Tinzaparin vs placebo

Number of serious complications of SCD ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Number of other sickle‐related events ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Hospitalisation (number and duration) ‐ not measured · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Tinzaparin vs placebo

Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Adverse events associated with the use of anticoagulants (e.g. bleeding) · people with sickle cell disease

Tinzaparin showed no clear difference in adverse events associated with the use of anticoagulants (e.g.… compared with placebo (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
RR 4.96 [0.24, 102.31]
1 study · 253 participants
Low

Intervention not reported

Days of catheter patency · Children with central venous catheter

1 finding from 1 review

Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Low

Intervention not reported

Catheter‐related thrombosis at any time during catheter stay · Children with central venous catheter

The intervention showed no clear difference in catheter‐related thrombosis at any time during catheter stay (moderate certainty).

1 finding from 1 review

Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
RR 0.34 [0.01, 7.68]
2 studies · 287 participants
Moderate

Intervention not reported

Occlusion of catheter within one week of catheter insertion · Children with central venous catheter

The intervention showed no clear difference in occlusion of catheter within one week of catheter insertion (low certainty).

1 finding from 1 review

Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
RR 0.06 [0, 1.07]
1 study · 200 participants
Low

Intervention not reported

Catheter‐related blood stream infection and CVC‐related colonization · Children with central venous catheter

The intervention may leads to lower catheter‐related blood stream infection and CVC‐related colonization (low certainty).

1 finding from 1 review

Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
RR 0.06 [0.01, 0.41]
1 study · 200 participants
Low

Intervention not reported

Side effects: Thrombocytopenia after catheter insertion · Children with central venous catheter

The intervention showed no clear difference in side effects: Thrombocytopenia after catheter insertion (low certainty).

1 finding from 1 review

Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
RR 0.73 [0.38, 1.39]
2 studies · 287 participants
Low

Intervention not reported

Live birth rate per woman · Subfertile women

It is very uncertain whether the intervention changes live birth rate per woman (very low certainty).

1 finding from 1 review

Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
OR 1.77 [1.07, 2.9]
3 studies · 386 participants
Very low

Intervention not reported

Clinical pregnancy rate per woman · Subfertile women

The intervention may leads to higher clinical pregnancy rate per woman (low certainty).

1 finding from 1 review

Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
OR 1.61 [1.03, 2.53]
3 studies · 386 participants
Low

Intervention not reported

Adverse effects · Subfertile women

1 finding from 1 review

Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
no estimate extracted
5 participants
GRADE not reported

Intervention not reported

Live birth rate per woman · Subfertile women

It is very uncertain whether the intervention changes live birth rate per woman (very low certainty).

1 finding from 1 review

Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
OR 1.85 [0.8, 4.24]
3 studies · 386 participants
Very low

Intervention not reported

Clinical pregnancy rate per woman · Subfertile women

The intervention showed no clear difference in clinical pregnancy rate per woman (low certainty).

1 finding from 1 review

Heparin for assisted reproduction 2013 · Cochrane Headline outcomes only
OR 1.66 [0.94, 2.9]
3 studies · 386 participants
Low